These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 36679976)
1. Identification of NS2B-NS3 Protease Inhibitors for Therapeutic Application in ZIKV Infection: A Pharmacophore-Based High-Throughput Virtual Screening and MD Simulations Approaches. Rehman HM; Sajjad M; Ali MA; Gul R; Irfan M; Naveed M; Bhinder MA; Ghani MU; Hussain N; Said ASA; Al Haddad AHI; Saleem M Vaccines (Basel); 2023 Jan; 11(1):. PubMed ID: 36679976 [TBL] [Abstract][Full Text] [Related]
2. Exploring the Lead Compounds for Zika Virus NS2B-NS3 Protein: an e-Pharmacophore-Based Approach. Rohini K; Agarwal P; Preethi B; Shanthi V; Ramanathan K Appl Biochem Biotechnol; 2019 Jan; 187(1):194-210. PubMed ID: 29911269 [TBL] [Abstract][Full Text] [Related]
3. Identification of RdRp inhibitors against SARS-CoV-2 through E-pharmacophore-based virtual screening, molecular docking and MD simulations approaches. Rehman HM; Sajjad M; Ali MA; Gul R; Naveed M; Aslam MS; Shinwari K; Bhinder MA; Ghani MU; Saleem M; Rather MA; Ahmad I; Amin A Int J Biol Macromol; 2023 May; 237():124169. PubMed ID: 36990409 [TBL] [Abstract][Full Text] [Related]
4. Structure-Based Virtual Screening: Identification of a Novel NS2B-NS3 Protease Inhibitor with Potent Antiviral Activity against Zika and Dengue Viruses. Shin HJ; Kim MH; Lee JY; Hwang I; Yoon GY; Kim HS; Kwon YC; Ahn DG; Kim KD; Kim BT; Kim SJ; Kim C Microorganisms; 2021 Mar; 9(3):. PubMed ID: 33800763 [TBL] [Abstract][Full Text] [Related]
5. Structure-based discovery of clinically approved drugs as Zika virus NS2B-NS3 protease inhibitors that potently inhibit Zika virus infection in vitro and in vivo. Yuan S; Chan JF; den-Haan H; Chik KK; Zhang AJ; Chan CC; Poon VK; Yip CC; Mak WW; Zhu Z; Zou Z; Tee KM; Cai JP; Chan KH; de la Peña J; Pérez-Sánchez H; Cerón-Carrasco JP; Yuen KY Antiviral Res; 2017 Sep; 145():33-43. PubMed ID: 28712942 [TBL] [Abstract][Full Text] [Related]
6. Identification of Montelukast as flavivirus NS2B-NS3 protease inhibitor by inverse virtual screening and experimental validation. Jiang H; Zhang Y; Wu Y; Cheng J; Feng S; Wang J; Wang X; Cheng M Biochem Biophys Res Commun; 2022 May; 606():87-93. PubMed ID: 35339757 [TBL] [Abstract][Full Text] [Related]
7. The discovery of Zika virus NS2B-NS3 inhibitors with antiviral activity via an integrated virtual screening approach. Mirza MU; Alanko I; Vanmeert M; Muzzarelli KM; Salo-Ahen OMH; Abdullah I; Kovari IA; Claes S; De Jonghe S; Schols D; Schinazi RF; Kovari LC; Trant JF; Ahmad S; Froeyen M Eur J Pharm Sci; 2022 Aug; 175():106220. PubMed ID: 35618201 [TBL] [Abstract][Full Text] [Related]
11. Discovery of Bispecific Lead Compounds from Kumar S; El-Kafrawy SA; Bharadwaj S; Maitra SS; Alandijany TA; Faizo AA; Khateb AM; Dwivedi VD; Azhar EI Molecules; 2022 Apr; 27(8):. PubMed ID: 35458761 [TBL] [Abstract][Full Text] [Related]
12. Structures and dynamics of peptide and peptidomimetic inhibitors bound to the NS2B-NS3 protease of the ZIKA virus. Pant S; Bhattacharya G; Jena NR J Biomol Struct Dyn; 2023 Apr; 41(7):3076-3088. PubMed ID: 35238272 [TBL] [Abstract][Full Text] [Related]
14. Identification of novel small molecule inhibitors against NS2B/NS3 serine protease from Zika virus. Lee H; Ren J; Nocadello S; Rice AJ; Ojeda I; Light S; Minasov G; Vargas J; Nagarathnam D; Anderson WF; Johnson ME Antiviral Res; 2017 Mar; 139():49-58. PubMed ID: 28034741 [TBL] [Abstract][Full Text] [Related]
15. Structure-guided screening of chemical database to identify NS3-NS2B inhibitors for effective therapeutic application in dengue infection. Bhowmick S; Alissa SA; Wabaidur SM; Chikhale RV; Islam MA J Mol Recognit; 2020 Jul; 33(7):e2838. PubMed ID: 32060998 [TBL] [Abstract][Full Text] [Related]
16. NS2B-NS3 protease inhibitors as promising compounds in the development of antivirals against Zika virus: A systematic review. Nunes DAF; Santos FRDS; da Fonseca STD; de Lima WG; Nizer WSDC; Ferreira JMS; de Magalhães JC J Med Virol; 2022 Feb; 94(2):442-453. PubMed ID: 34636434 [TBL] [Abstract][Full Text] [Related]
18. Repurposing of antiparasitic drugs against the NS2B-NS3 protease of the Zika virus. Pant S; Jena NR J Biomol Struct Dyn; 2024; 42(19):10101-10113. PubMed ID: 37747074 [TBL] [Abstract][Full Text] [Related]
19. Identification of Zika Virus NS2B-NS3 Protease Inhibitors by Structure-Based Virtual Screening and Drug Repurposing Approaches. Santos FRS; Nunes DAF; Lima WG; Davyt D; Santos LL; Taranto AG; M S Ferreira J J Chem Inf Model; 2020 Feb; 60(2):731-737. PubMed ID: 31850756 [TBL] [Abstract][Full Text] [Related]
20. Flavonoids from Pterogyne nitens as Zika virus NS2B-NS3 protease inhibitors. Lima CS; Mottin M; de Assis LR; Mesquita NCMR; Sousa BKP; Coimbra LD; Santos KB; Zorn KM; Guido RVC; Ekins S; Marques RE; Proença-Modena JL; Oliva G; Andrade CH; Regasini LO Bioorg Chem; 2021 Apr; 109():104719. PubMed ID: 33636437 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]